with very low rates of discontinuation due to treatment-related adverse events Pimicotinib is being developed by Abbisko Therapeutics Co., Ltd.; Merck holds commercial license for pimicotinib in ...

The drug is being developed by the Chinese biotech Abbisko Therapeutics Co. Merck KGaA holds commercial license for Pimicotinib in Chinese mainland, Hong Kong, Macau, and Taiwan, it said.

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced a $76 million expansion of its ADC manufacturing ...

The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Aktis is also eligible to receive up to $1.1 billion based on development, regulatory and commercial milestones. The biotech would also be eligible for royalties. As of earlier this year ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

A key panel of U.S. health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and Merck & Co. that protect against pneumococcal disease, clearing a path ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...